Bonnie W. Leung

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

Guihong Wan, Nga Nguyen, Charles Lu, Sara Khattab et autres

Importance: Systemic glucocorticoid immunosuppression (gsISP) is commonly used among patients receiving immune checkpoint inhibitor (ICI) therapy, but the associations of gsISP timing, dose, and duration with overall survival (OS) remain incompletely characterized. Objective: To examine the associations of gsISP timing, dose, and …

us (code pays fourni par la source)

Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors

Marjan Azin, Parisa Farokh, Bonnie W. Leung, Hannah Rashdan et autres

us (code pays fourni par la source)

Effect of systemic glucocorticoid immunosuppression timing, dose, and duration on overall survival among immune checkpoint inhibitor recipients: a retrospective multicohort study

Guihong Wan, Nga Nguyen, Charles Lu, Sara Khattab et autres

Summary Background Systemic immunosuppression (sISP), particularly with glucocorticoids, is commonly used among patients receiving immune checkpoint inhibitor (ICI) therapy. Although recent studies have demonstrated that sISP is associated with poor outcomes in ICI recipients, there is limited information on how the timing, …

us (code pays fourni par la source)

Machine learning prediction for early-stage melanoma outcomes: recurrence-free survival, disease-specific survival, and overall survival

Guihong Wan, Hannah Rashdan, Olivia Burke, Sara Khattab et autres

This study compared machine-learning models for predicting recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) using clinicopathologic data from 1,621 stage I/II primary cutaneous melanoma patients. Our time-to-event models achieved concordance indices of 0.829 for RFS, 0.812 for DSS, and …

us (code pays fourni par la source)

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Sara Khattab, Guihong Wan, Suzanne Xu, Cameron Moseley et autres

BACKGROUND: Dupilumab has been added to National Cancer Comprehensive Network guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint blockade (ICB). However, little is known about the implications of dupilumab for cancer outcomes in this …

us (code pays fourni par la source)

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Sara Khattab, Guihong Wan, Suzanne Xu, Cameron Moseley et autres

Background: Dupilumab has been added to National Cancer Comprehensive Network (NCCN) guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitor (ICI) therapy. However, little is known about the implications of dupilumab for cancer outcomes …

us (code pays fourni par la source)

784 Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitor therapy

Marjan Azin, Alice McGarry, Bonnie W. Leung, Katie Roster et autres

us (code pays fourni par la source)

Surgical margin reduction in excision of cutaneous melanoma: A retrospective analysis

Ahmad Rajeh, Katie Roster, Nga Nguyen, Bonnie W. Leung et autres

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

us (code pays fourni par la source)

Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study

Guihong Wan, Sara Khattab, Bonnie W. Leung, Shijia Zhang et autres

BACKGROUND: Cutaneous immune-related adverse events (cirAEs) are the most common toxicities to occur in the setting of immune checkpoint inhibitor (ICI) therapy. Identifying patients who are at increased risk of developing cirAEs may improve quality of life and outcomes. OBJECTIVES: To investigate …

us (code pays fourni par la source)

554 Clinical outcomes of patients treated with immune checkpoint inhibitor therapy for early-stage melanoma recurrence: a retrospective cohort study

Nga Nguyen, Guihong Wan, Hannah Rashdan, Bonnie W. Leung et autres

Background Melanoma mortality has steadily decreased since the introduction of immune checkpoint inhibitors (ICIs) to manage advanced-stage disease (stage III/IV).1 Although ICIs have prolonged survival, this therapeutic class is associated with toxicities, of which cutaneous immune-related adverse events (cirAEs) are the most …

us (code pays fourni par la source)

1273 Effect of systemic immunosuppression timing on overall survival among immune checkpoint inhibitor recipients

Guihong Wan, Nga Nguyen, Boshen Yan, Munachimso Amadife et autres

Background High-dose systemic immunosuppression (ISP) is associated with poorer survival outcomes in cancer patients treated with immune checkpoint inhibitors (ICIs).1–3 However, the effect of ISP timing on survival is not well-studied. The aim of this retrospective study is to examine the association …

us (code pays fourni par la source)

Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

Guihong Wan, Nga Nguyen, Bonnie W. Leung, Hannah Rashdan et autres

us (code pays fourni par la source)